Stock Traders Purchase Large Volume of Anteris Technologies Global Call Options (NASDAQ:AVR)

Anteris Technologies Global Corp. (NASDAQ:AVR) was the recipient of unusually large options trading on Thursday. Stock investors purchased 7,578 call options on the company. This is an increase of 2,203% compared to the average volume of 329 call options.

Anteris Technologies Global Stock Performance

Shares of NASDAQ:AVR traded up $0.66 on Thursday, hitting $9.61. 530,676 shares of the company’s stock were exchanged, compared to its average volume of 1,136,380. The firm’s 50-day moving average is $6.66 and its 200 day moving average is $5.79. The company has a market capitalization of $935.44 million, a PE ratio of -4.34 and a beta of 1.78. Anteris Technologies Global has a 1-year low of $2.85 and a 1-year high of $10.14.

Anteris Technologies Global (NASDAQ:AVR) last issued its earnings results on Tuesday, May 12th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.01). The business had revenue of $0.49 million for the quarter, compared to analysts’ expectations of $0.77 million. Anteris Technologies Global had a negative return on equity of 124.76% and a negative net margin of 5,148.78%.During the same period last year, the company posted ($0.61) earnings per share. On average, analysts anticipate that Anteris Technologies Global will post -1.14 EPS for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have recently issued reports on AVR. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $15.00 price target on shares of Anteris Technologies Global in a research note on Friday, March 27th. Weiss Ratings reissued a “sell (d-)” rating on shares of Anteris Technologies Global in a research note on Friday, May 29th. Barclays boosted their price objective on Anteris Technologies Global from $17.00 to $18.00 and gave the stock an “overweight” rating in a research note on Friday, May 15th. Wall Street Zen raised Anteris Technologies Global from a “sell” rating to a “hold” rating in a research note on Saturday, May 16th. Finally, Wells Fargo & Company initiated coverage on Anteris Technologies Global in a research note on Wednesday, March 11th. They set an “overweight” rating and a $16.00 price objective on the stock. Four analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, Anteris Technologies Global currently has a consensus rating of “Moderate Buy” and a consensus price target of $16.00.

Institutional Investors Weigh In On Anteris Technologies Global

Hedge funds have recently made changes to their positions in the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in shares of Anteris Technologies Global in the first quarter worth about $32,000. Geode Capital Management LLC lifted its stake in shares of Anteris Technologies Global by 154.3% in the second quarter. Geode Capital Management LLC now owns 420,427 shares of the company’s stock worth $1,593,000 after acquiring an additional 255,088 shares in the last quarter. JPMorgan Chase & Co. lifted its stake in shares of Anteris Technologies Global by 9,958.6% in the second quarter. JPMorgan Chase & Co. now owns 1,068,328 shares of the company’s stock worth $4,049,000 after acquiring an additional 1,057,707 shares in the last quarter. Nantahala Capital Management LLC lifted its stake in shares of Anteris Technologies Global by 1.8% in the second quarter. Nantahala Capital Management LLC now owns 1,693,666 shares of the company’s stock worth $6,419,000 after acquiring an additional 30,000 shares in the last quarter. Finally, Vanguard Group Inc. lifted its stake in shares of Anteris Technologies Global by 85.1% in the third quarter. Vanguard Group Inc. now owns 745,560 shares of the company’s stock worth $3,355,000 after acquiring an additional 342,711 shares in the last quarter.

Anteris Technologies Global Company Profile

Anteris Technologies Global Corp. engages in the development and commercialization of medical devices for heart diseases. The company was founded in 1999 and is headquartered in Eagan, MN.